Today: 30 June 2026
Browse Category

ASX:TLX 11 December 2025 - 10 April 2026

Australia Stock Market Today: ASX 200 Ends Lower but Still Logs Best Week Since 2022

Australia Stock Market Today: ASX 200 Ends Lower but Still Logs Best Week Since 2022

Australian shares finished in the red on Friday, but the benchmark still managed its best weekly showing since late 2022. A possible U.S.-Iran truce helped the week’s relief rally hold. The S&P/ASX 200 gave up 12.6 points, or 0.14%, to close at 8,960.6. BHP dropped 1.1%, Fortescue lost 1.3%, and Santos slipped 0.6%. Australia’s exposure to the six-week Middle East war has been pronounced, given the Strait of Hormuz—a tight Gulf corridor accounting for nearly a fifth of global oil trade—has kept both supply jitters and inflation risks front and center. The ASX 200 still managed to close the week higher by about 4.4%, despite Friday’s dip. With U.S.-Iran talks set for the weekend in Islamabad, the ceasefire remains far from secure.
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2 On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of roughly 6.36 million shares—a notably volatile day by recent standards. Investing.com+1
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story.

Stock Market Today

  • Indian Shares Edge Up as Bank Stocks Climb After HDFC Bank Reshuffle
    June 30, 2026, 12:24 AM EDT. Indian shares opened up on Tuesday, with bank stocks leading gains after a top management reshuffle at HDFC Bank, the largest private lender. HDFC Bank is making leadership changes as it adapts to market pressures. A quieter Middle East also steadied crude oil prices, holding volatility in check. Financials outperformed energy and commodity names. Sentiment got a lift from the governance moves and less tension in geopolitics.
Go toTop